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ORIGINAL ARTICLE
Waldenstro¨m’s macroglobulinemia harbors a unique proteome
where Ku70 is severely underexpressed as compared with
other B-lymphoproliferative disorders
A Perrot1,2,3, C Pionneau4,5, N Azar6, C Baillou5,7, FM Lemoine5,7, V Leblond5,6, H Merle-Be´ral5,6, M-C Be´ne´3, R Herbrecht8, S Bahram1,2,9
and L Vallat1,2,9
Waldenstro¨m’s macroglobulinemia (WM) is a clonal B-cell lymphoproliferative disorder (LPD) of post-germinal center nature.
Despite the fact that the precise molecular pathway(s) leading to WM remain(s) to be elucidated, a hallmark of the disease is the
absence of the immunoglobulin heavy chain class switch recombination. Using two-dimensional gel electrophoresis, we compared
proteomic proﬁles of WM cells with that of other LPDs. We were able to demonstrate that WM constitutes a unique proteomic
entity as compared with chronic lymphocytic leukemia and marginal zone lymphoma. Statistical comparisons of protein expression
levels revealed that a few proteins are distinctly expressed in WM in comparison with other LPDs. In particular we observed a major
downregulation of the double strand repair protein Ku70 (XRCC6); conﬁrmed at both the protein and RNA levels in an independent
cohort of patients. Hence, we deﬁne a distinctive proteomic proﬁle for WM where the downregulation of Ku70—a component of
the non homologous end-joining pathway—might be relevant in disease pathophysiology.
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INTRODUCTION
Waldenstro¨m’s macroglobulinemia (WM)—alternatively desig-
nated as lymphoplasmacytic lymphoma—is an uncommon B-cell
lymphoproliferative disorder (LPD) characterized primarily by a
lymphoplasmacytic inﬁltration of the bone marrow and by an
immunoglobulin M monoclonal gammapathy.1,2
Although the precise molecular path(s) leading to WM remain
largely unknown, there is clear evidence for the post-germinal
center nature of the WM clonal cells, as the IGH (immunoglobulin
heavy chain gene) is almost always subjected to somatic hyper-
mutation;3,4 although without the presence of any intraclonal
variation.5,6 Moreover and in contrast to immunoglobulin M
multiple myeloma (MM) and chronic lymphocytic leukemia (CLL),
post-switch clonotypic immunoglobulins are undetectable in WM
B cells, suggesting therefore that absence of isotype switching;5,6
although the latter could be achieved in vitro in response
to appropriate stimuli for example, CD40-ligand and IL-4.7
Immunoglobulin class switching requires a functional activation-
induced cytidine deaminase8 and uses the robust non
homologous end-joining (NHEJ) pathway.9 The Ku (Ku70/Ku80)
heterodimer is a key factor in this pathway, acting as a scaffold
for the recruitment of NHEJ core or such processing factors as the
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and
the XRCC4/ligase IV complex.10,11
To progress in the understanding of molecular pathway(s)
underlying the advent of the disease, gene-expression proﬁling
of WM cells has been previously performed; revealing a
homogeneous expression proﬁle, more similar to that of CLL than
that of MM.12 A small set of genes was thereafter identiﬁed to be
distinctly expressed in WM. They include interleukin-6 (IL6) and
genes of the mitogen-activated protein kinase pathway.
Upregulation of IL6 in WM was conﬁrmed by an independent
study.13 Aiming to compare WM cells with B-cell morphology and
those with plasma cell morphology, this work concluded that
B cells and plasma cells from WM patients exhibit distinct patterns
of gene expression as compared with B cells and plasma cells from
patients with CLL and MM.13
Few proteomic studies have been performed in WM. These
include a proteomic analysis of signaling pathways performed
in WM and MM samples, before and after treatment with a
proteasome inhibitor.14 Clustering analysis allowed to identify
proteins that were expressed by either of these disorders but not
both, indicating differences in cellular responses to proteasome
inhibition.14 Hatjiharissi et al.15on the other hand compared—
using an antibody-based protein microarray method—the
patterns of protein expression between untreated WM cells
and normal bone marrow controls. These analyses identiﬁed
upregulation of proteins of the Ras and Rho family, as well as of
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cyclin-dependent kinases, apoptosis regulators and histone
deacetylases.15 Moreover, high expression of the heat shock
protein HSP90 was observed in cells from symptomatic WM
patients.15
Here, we aimed to perform a comprehensive proteomic analysis
of WM versus closely linked diseases with likely overlapping
pathophysiologies. Similarly to our recent work in CLL16 and using
a two-dimensional gel electrophoresis (2D-E) approach,17 we
compared WM with marginal zone lymphoma (MZL) and CLL.
Three notable lessons were learnt in this study: (1) in contrast to
observations using gene-expression proﬁling and limited
proteomic analyses where WM is quasi indistinguishable from
CLL, MM or normal B cells, we demonstrate a—statistically
signiﬁcant—distinct proteomic content for WM versus other LPDs;
(2) we establish the existence for WM, of 17 majorly differentially
expressed proteins in the same comparative analyses; (3) among
the latter, we identify Ku70, part of the Ku heterodimer, and
directly involved in class switch recombination, as one of the most
differentially underexpressed proteins in WM cells as compared
with other B-cell LPDs.
PATIENTS AND METHODS
Patients and B-cell selection
Twenty six untreated patients with LPD (10 WM, 4 MZL, 10 CLL and 2
mantle cell lymphoma; MCL), were enrolled in this study. Peripheral blood
and/or bone marrow were obtained for each patient after informed
consent in accordance with the Helsinki Declaration. Clinical and biological
features of all patients are provided in Table 1. Cells corresponding to
3 WM, 3 MZL and 4 CLL samples were used for 2D-E analysis, whereas
those from, respectively, 9 (4 WM, 3 MZL and 2 CLL) and 14 (5 WM, 2 MZL,
5 CLL and 2 MCL) untreated patients were used for western blot and
quantitative RT-PCR experiments. B cells—for all LPDs with the exception
of WM and MZL used in 2D-E—were puriﬁed by negative selection using
the Rosettesep B-cell enrichment cocktail (StemCell Technologies, Van-
couver, Canada) followed by density gradient centrifugation on Ficoll-
Paque PLUS (GE Healthcare, Saclay, France). B cells from whole blood or
bone marrow of WM and MZL patients analyzed in 2D-E were sorted by
ﬂow cytometry (FACSAria II, Becton Dickinson, Le Pont-De-Claix, France)
using anti-CD19 monoclonal antibody (CD19-PerCP Cy5.5, BD Biosciences,
Le Pont de Claix, France), kappa or lambda monotypy (kappa-FITC/lambda-
PE, Dako) and the immunophenotypic characteristics of the malignant
clone (CD79b for the MZL2 patient) (CD79b-APC, BD Biosciences). The
purity of samples isolated by rosette and ﬂow cytometry sorting cells was
495%; often 497%.
2D-ELECTROPHORESIS (2D-E)
Ten samples were used in 2D-E analysis. For each cell suspension,
total proteins were extracted in iso-electric focusing-speciﬁc lysis
buffer containing 7 M urea, 2 M thiourea, 1% CHAPS, 10%
isopropanol, 10% isobutanol, 0.5% Triton X100, 0.5% SB3-10,
30mM Tris, 65mM DTT, 0.5% IPG buffer 3–10 and 30mM spermine.
After centrifugation at 16 000 g for 30min at 4 1C, proteins were
precipitated with the Perfect-Focus Kit from G-Biosciences
(Maryland, Heights, MO, USA) and resuspended in a buffer
containing 7 M urea, 2 M thiourea, 1% CHAPS, 10% isopropanol,
10% isobutanol, 0.5% Triton X100, 0.5% SB3-10 and 30mM Tris.
The total protein concentration of each sample was established
using the Bradford assay (Protein Assay, Bio-rad, Ivry sur Seine,
France) with bovine serum albumin as standard. All protein
extracts (50 mg per sample) were labeled using ﬂuorescent
Cyanine (Cy) dyes, as per the manufacturer’s instructions for
minimal labeling (GE Healthcare). Cy3 and Cy5 were alternatively
used to label protein extracts according to the dye switch method.
For each gel, two labeled protein extracts—expected to
Table 1. Patients’ characteristics
Samples Origin Experiments Patient’s age Patient’s sex Diagnosis Cytogenetics
WM1_BM Bone marrow 2D-E and qPCR 79 M WM (IgM kappa) Trisomy 4
WM1_B Blood 2D-E
WM2_B Blood 2D-E 66 M WM (IgM kappa) Undetermined
WM3_BM Bone marrow WB 72 M WM (IgM kappa) Undetermined
WM4_B Blood WB 58 M WM (IgM kappa) Undetermined
WM5_BM Bone marrow WB 59 F WM (IgM kappa) Normal
WM6_BM Bone marrow WB 59 M WM (IgM kappa) Undetermined
WM7_BM Bone marrow qPCR 63 F WM (IgM lambda) Undetermined
WM8_BM Bone marrow qPCR 64 M WM (IgM kappa) Undetermined
WM9_BM Bone marrow qPCR 51 M WM (IgM lambda) Normal
WM10_BM Bone marrow qPCR 32 M WM (IgM kappa) Undetermined
MZL1_B Blood 2D-E 61 F MZL (IgM kappa) Undetermined
MZL2_B Blood 2D-E 57 F MZL (IgM lambda) Trisomy 18 and 3
MZL2_BM Bone marrow 2D-E and WB
MZL3_BM Bone marrow WB and qPCR 59 F MZL (IgM kappa) Undetermined
MZL4_B Blood WB and qPCR 64 F MZL (IgM kappa) Normal
CLL1 Blood 2D-E 89 M CLL (IGH unmutated) Deletion 11q
CLL1’ Blood 2D-E
CLL2 Blood 2D-E 67 F CLL (IGH unmutated) Deletions 13q and 17p
CLL3 Blood 2D-E 64 M CLL (IGH mutated) Normal
CLL4 Blood WB 77 M CLL (IGH undetermined) Deletion 13q
CLL5 Blood WB 78 M CLL (IGH mutated) Trisomy 12
CLL6 Blood qPCR 54 M CLL (IGH unmutated) Deletions 16q and 17p
CLL7 Blood qPCR 52 M CLL (IGH mutated) Normal
CLL8 Blood qPCR 78 M CLL (IGH undetermined) Undetermined
CLL9 Blood qPCR 79 F CLL (IGH undetermined) Deletion 13q
CLL10 Blood qPCR 72 M CLL (IGH undetermined) Undetermined
MCL1_BM Bone marrow qPCR 65 M MCL t(11;14)
MCL2_B Blood qPCR 57 M MCL t(11;14)
Abbreviations: CLL, chronic lymphocytic leukemia; IGH, immunoglobulin heavy chain gene; IgM, immunoglobulin M; MCL, mantle cell lymphoma;
MZL, marginal zone lymphoma; qPCR, quantitative polymerase chain reaction; WB: western-blot; WM, Waldenstro¨m’s macroglobulinemia; 2D-E,
two-dimensional electrophoresis.
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co-migrate—were mixed to a strip’s rehydration buffer containing
7 M urea, 2 M thiourea, 1% CHAPS, 10% isopropanol, 10%
isobutanol, 0.5% Triton X100, 0.5% SB3-10, 40mM DTT and 0.5%
IPG buffer 4–7 for a total volume of 460ml. Rehydration of a 24 cm
Immobiline pH 4–7 DryStrip (GE Healthcare) was achieved in the
dark during 16 h. Iso-electric focusing was then performed at 20 1C
for a total of 85 000 Vh using the Ettan II IPGphor system
(GE Healthcare). After migration, the strips were equilibrated in
SDS containing buffer (reduction and alkylation) before being
loaded onto SDS polyacrylamide gels for separation according to
molecular weight using an Ettan DALT Six Electrophoresis System
(GE Healthcare). After migration, 2D-E gels were scanned using an
Ettan DIGE Imager (GE Healthcare) according to the manufac-
turer’s instructions. Image analysis and statistical calculations were
performed using the Progenesis SameSpots software (NonLinear
Dynamics, Newcastle, UK) and the ‘Multiple stains per gel without
internal standards’ comparison method. All sample gel images
were ﬁrst aligned. Spots were then automatically detected and
ﬁltered to eliminate non-protein spots. Statistical analyses
(analysis of variance and principal component analyses) were
performed on normalized spots data. For multigroup analysis of
variance test, a q-value (a FDR corrected P-value) of o0.05 was
considered signiﬁcant. The threshold chosen to appreciate
variations was a 2.5-fold change when comparing WM versus
CLL groups.
Protein identiﬁcation
Analytical gels were stained with SYPRO Ruby (Invitrogen
Corporation, Carlsbad, CA, USA) and used for robotized spot
picking (EXQuest spot cutter, Bio-Rad, Marnes-la-Coquette,
France). Gel plugs were washed twice with 25mM ammonium
bicarbonate in 50% acetonitrile then dehydrated in 100%
acetonitrile, before being subjected to overnight in-gel trypsic
digestion. Brieﬂy, each spot was incubated in a solution containing
50mM ammonium bicarbonate, 10% acetonitrile and 20 mg/ml
trypsin (G-Biosciences) on ice during 1 h, then overnight at 37 1C.
The supernatants were collected and gel plugs were incubated in
0.1% TFA 50% acetonitrile in an ultrasonic bath during 10min to
extract residual peptides. The new supernatants were pooled
with the former. Peptides were dried completely in a vacuum
centrifuge then resuspended in 0.1% TFA 50% acetonitrile, to be
analyzed by mass spectrometry (MS or MS/MS). Peptides were
spotted onto a MALDI plate with matrix solution (50% acetonitrile,
0.1% TFA, HCCA at saturation) diluted four-fold in 50% acetonitrile,
0.1% TFA and analyzed by MS using an Autoﬂex MALDI-TOF
(Bruker Daltonics, Bremen, Germany). This instrument was
operated in positive ion mode and externally calibrated in the
peptide mass range of 700–3200m/z. MS/MS analysis was
performed using the Ultimate 3000 nanoLC system (Dionex, Voisin
le Bretonneux, France) coupled to an Esquire HCTultra nESI-IT-MS
(Bruker Daltonics). A search for protein identity was carried out with
MASCOT (http//www.matrixscience.com). Conﬁdent matches were
deﬁned by the MASCOT score and statistical signiﬁcance (Po0.05),
the number of matching peptides and the percentage of total
amino acid sequences covered by matching peptides.
Western-blot analysis
Cell lysates were prepared by incubating puriﬁed B-cell pellets on
ice for 30min in 200ml of a lysis buffer containing 150mM NaCl,
50mM Tris pH8, 1% NP40, 10% glycerol, 0.5mM EDTA and protease
inhibitor Complete 1X (Roche Diagnostics, Mannheim, Germany).
The samples were then centrifuged at 4 1C for 30min at 16 000 g.
Samples containing 50 mg of protein were mixed with Laemmli
buffer 1X and boiled for 5min. Protein extracts were separated on
10% SDS–PAGE, then transferred to nitrocellulose membranes
(Hybond-C Extra, Amersham Biosciences, Buckinghamshire, UK).
Nonspeciﬁc binding sites were blocked for 1 h in 5% milk in T-TBS
(50mM Tris, 150mM NaCl, 0.5% Tween-20). The membranes were
then probed with anti-Ku (p70) (clone N3H10, Kamiya Biomedical,
Seattle, WA, USA) during 3 h at room temperature. After thorough
washing in T-TBS, incubation was carried out for 1 h in the
presence of horseradish peroxidase-conjugated anti-mouse IgG
(Bio-Rad Laboratories, Hercules, CA, USA). All immunoblots were
revealed by enhanced chemiluminescence using the Super Signal
West Pico Substrate (Pierce Biotechnology, Inc., Rockford, IL, USA).
Data were acquired by scanning-densitometry using a Chemi-Start
(Vilber-Lourmat, Marne-La-Valle´e, France).
Quantitative real-time RT-PCR
A quantitative real-time RT-PCR ampliﬁcation of XRCC6 (encoding
Ku70) was performed as a second validation test. This was
achieved for 14 subjects, respectively, 5 WM and 9 others B LPD
including MZL (n¼ 2), MCL (n¼ 2) and CLL (n¼ 5). Brieﬂy, total
RNA was extracted using the RNeasy mini kit (Qiagen, Courta-
boeuf, France) and treated with DNase (Qiagen). cDNA was
synthesized using Improm II reverse transcriptase (Promega, Lyon,
France) and random hexadeoxynucleotide primers (Promega). The
relative gene expression of XRCC6 was determined by concomi-
tant ampliﬁcation of GUSB (beta-D glucuronidase) as a reference
gene using a LightCycler 480 (Roche). Assays were performed in
duplicate using 5 ml of cDNA, 1X Taqman Universal Master Mix
(Applied BioSystems, Warrington, UK) and 1X TaqMan Gene
Expression Assays (Applied Biosystems, Foster City, CA, USA) for
XRCC6 and GUSB in a total volume of 25 ml. LightCycler 480
Software (Roche) was used to calculate the relative gene
expression of XRCC6 (2DDCT method).
RESULTS
Here we present a ﬁrst comprehensive 2D-E analysis of WM versus
other LPDs.
WM is a unique proteomic entity
Quantitative proteomic analysis by 2D-E was performed for 10
protein extracts obtained from B cells isolated from peripheral
blood and/or bone marrow of 2 WM (3 samples), 2 MZL
(3 samples) and 3 CLL (4 samples) patients. The inclusion of
blood and bone marrow cells from the same patients (WM1 and
MZL2) was aimed to foresee the extent to which cell origin/
developmental stage might have any inﬂuence in proteomic
proﬁle in a same individual.
Multivariate analysis of protein expression was ﬁrst performed
using a principal component analysis. Used as an explorative tool
to investigate the clustering of all WM, MZL and CLL samples,
principal component analysis analysis demonstrated that WM
clustered distinctly from MZL and CLL (Figure 1). Hence, the
protein content of WM cells is signiﬁcantly different from those of
MZL or CLL. Of note, one WM and one MZL patient segregated
quite differently in principal component analysis, although with-
out overlapping with other LPDs, and the ‘stray’ WM patient still
was nearest to the other two (Figure 1).
Several proteins are differentially expressed in WM as
compared with MZL and CLL
Among the 1051 polypeptide spots analyzed within different
samples, 356 showed a differential expression. Most differentially
expressed polypeptide spots (with a 2.5-fold change) between
WM and CLL samples, and between WM and MZL samples, as
identiﬁed by mass spectrometry, are presented in Table 2. The ﬁrst
highlight from this analysis is that the detected differentially
expressed proteins are not—for the vast majority—among
the candidate genes/proteins, which would have expected to be
critical in WM—that is, in direct connection with leukomogenesis,
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immune-related loci and so on—but are rather conﬁned
to ubiquitously expressed structural/housekeeping proteins for
example, cytoskeleton, metabolism. Remarkably the vast majority
of these proteins show a similar expression pattern that is, up/
downregulation in WM vs CLL or MZL hinting again to the fact
that WM harbors a distinct proteome entity versus these two other
closely considered LPDs. A few notable distinctly expressed
proteins are the following: phosphoglucomutase-2 and annexin
A6, which were strongly overexpressed, especially when compar-
ing WM and CLL; conversely, peroxiredoxin and Ku70 (X-ray
repair cross-complementing protein 6), showed the strongest
downregulation in WM compared with CLL. The same trend,
although less pronounced, was observed between WM and MZL.
Several components of the cytoskeleton were also differentially
expressed in WM cells, namely moesin, gelsolin and lamin-B1.
Ku70 proteomic proﬁle was examined more thoroughly: 2D and
3D representations together with statistical expression data are
shown in Figure 2. No variation of the proteomic content between
blood and bone marrow cells, neither for WM nor MZL was noted
for this protein.
Lower expression of Ku70 (XRCC6) protein and gene expression in
WM cells by comparison with other LPDs
Ku70 was—for obvious reasons of its direct implication in
immunoglobulin class switching—the candidate protein retained
for validation on a larger cohort of patients. First, western
blot experiments performed on 9 untreated patients (whose
characteristics are summarized in Table 1) clearly conﬁrmed a much
lower expression that is, quasi absence of Ku70 in WM as compared
with MZL and CLL (Figure 3). Second, in order to investigate whether
the quantitative defect of Ku70 protein was related to a lack of XRCC6
RNA transcript or to a post-translational process, gene expression of
XRCC6 was assessed using quantitative RT-PCR (using GUSB as
reference gene) in 14 patients with WM or other lymphoid
malignancies. XRCC6 expression was found to be signiﬁcantly lower
in MW cells as compared with other LPDs including MZL, CLL and
MCL (Figure 4); thus suggesting that the observed protein down-
regulation was due to a transcriptional shut down.
DISCUSSION
WM, a rare, distinct, B LPD, is deﬁned by lymphoplasmacytic
inﬁltration of the bone marrow and a monoclonal immunoglobulin
M paraproteinemia, respectively, ascertained by bone marrow
biopsy and serum protein immunoelectrophoresis/immunoﬁxa-
tion. However, before performing the latter tests in order to reach
diagnostic certitude, there is/are at present no unique non
invasive diagnostic biomarker(s) available helping to guide the
clinician in an often diversity of nonspeciﬁc early symptoms for
example, fatigue, anemia, thrombocytopenia, hepatosplenome-
galy and lymphadenopathy.
Array technology, especially transcriptome analysis, has been
widely used in clonal hematological malignancies.18,19 WM has not
escaped this trend, as mentioned earlier. Proteome analysis—
more cumbersome presently—has been less widely used and in
case of WM has been performed in only two reports with self
imposed limitations/biases. Here, we present a ﬁrst comprehen-
sive 2D-E analysis of WM, as compared with other LPDs. This study
yielded more signiﬁcant differences for 17 proteins (Table 2).
Besides, the possibly critical downregulation of Ku70, a few other
modiﬁcations of housekeeping/structural proteins were observed.
These include molecules involved in glucose metabolism, redox
balance, cell communication, protein metabolism, regulation of
translation or nucleic acid binding. Phosphoglucomutase-2
appears to be selectively overexpressed in WM compared with
CLL and MZL.20,21 Inversely, glutaredoxin-3 (GLRX3), lactoyl-
glutathione lyase (GLO1) and peroxiredoxin-6 (PRDX6) appeared
to be underexpressed in WM cells as compared with CLL and MZL
cells.22 GLO1 belongs to the glyoxalase complex, which catalyzes
the conversion of methylglyoxal to D-lactate.23 Peroxiredoxins are
a ubiquitous family of antioxidant enzymes that functions as
tumor suppressor to certain haematopoietic cancers in mice.24
PRDX6, the most underexpressed protein in WM in our study, is a
bifunctional enzyme having both peroxidase and phospholipase
A2 activities, with roles in oxidative stress-induced and
TNF-induced apoptosis.25
Cytoskeleton proteins also appeared to be differentially
expressed in WM. Gelsolin is an actin-binding protein that is a
key regulator of actin ﬁlament assembly and disassembly.26,27
Gelsolin has been reported increased in vincristine (an anti-
microtubule agent)-resistant acute leukemia, whilst moesin was
decreased in the same cells.28 Moesin, which expression was
decreased in WM in our study, is a member of the ERM protein
family, which appears to function as cross-linker between plasma
membranes and actin-based cytoskeletons for cell–cell recogni-
tion, signaling and cell movement phenomena. Finally,
we observed that several isoforms of annexin A6, a calcium-
dependent membrane-binding protein, were upregulated in
WM cells.29
Again, perhaps the most notable alteration observed in our
study was the silencing of Ku70 in WM cells. This was further
conﬁrmed by western blot and mRNA analysis in a second cohort
of patients, strengthening the consistency of this anomaly. The Ku
(Ku70/Ku86) heterodimer was ﬁrst discovered as an auto-antigen
in patients with autoimmune disorders.30 The genes encoding
these proteins are located on chromosomes 22q13 and 2q33-35.31
Ku is the DNA-targeting subunit of a DNA-dependent protein
kinase (DNA-PK), which is a serine/threonine kinase consisting of a
465-kDa catalytic subunit (DNA-PKcs) and the heterodimeric Ku
regulatory complex. The latter binds to DNA double-stranded ends
and other discontinuities in the DNA32 and recruits the DNA-PKcs
of the complex.33 Classical NHEJ involves the DNA–PK complex,
essential for lymphoid development, especially VDJ recombination
and Ig switching. Indeed Ku70 / mice lack B-cell maturation
and the absence of Ku70 confers hypersensitivity to ionizing
radiation and deﬁciency in DNA double-stranded breaks
repair,34 translating in an extreme radiosensitivity and speciﬁc
VDJ recombination defects,35–37 as well as high levels of
chromosomal aberrations.38,39 In man, DNA-PK activity and
increased expression of both Ku70 and Ku86 have been shown
to correlate with resistance to therapeutic molecules notably in
Figure 1. Principal component analysis (PCA) distinguishes WM, MZL
and CLL cells. PCA as a ‘score plot’ of a spot map of the 10 protein
extracts (3 WM, 3 MZL and 4 CLL) color-coded according to the
legend, projected onto the first two principal components. The PC1
and PC2 axes segregate WM samples (pink spots) from both MZL
(purple spots) and CLL (blue spots) groups.
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the context of CLL.40 Minor defects in the NHEJ pathway moreover
have been shown to confer predisposition to leukemia.41 Most
LPDs arise via transformation of post-germinal center B cells
with chromosomal mutations.42 Immunodeﬁciencies with both
abnormal DNA repair43 and genetic polymorphisms of NHEJ
components44,45 have been associated to an increased
susceptibility to the development of lymphoid malignancies,
suggesting that an aberrant NHEJ pathway could lead to
lymphomagenesis. However, when investigated, no mutation or
deletion of Ku86 has been observed in CLL or acute lymphoblastic
leukemia cells.46 Acute lymphoblastic leukemia cells were found
to express high levels of DNA-PKcs, Ku86 and Ku70 protein,
whereas CLL cells displayed a lower expression of DNA-PKcs and
Ku86 but not Ku70.47 By quantitative RT-PCR in several types of
LPD (not including WM), a lower expression of Ku70-encoding
XRCC6 gene was observed compared with reactive lymph nodes.48
Figure 2. 2D-E analysis of Ku70 protein expression. Spots were analyzed with Progenesis SameSpots (NonLinear Dynamics). (a) Representative
focus of the Ku70 protein (spot no. 712) on WM, MZL and CLL samples 2D-gel images. (b) 3D-representation of the Ku70 volume ratios
difference between WM, MZL and CLL samples. (c) Statistical analysis of spot no. 712: significant decrease of Ku70 expression in WM cells as
compared with CLL cells (*Po0.05).
Figure 3. Western-blot validation of the Ku70 2D-E profile. Western
blot results of Ku70 expression in samples from WM, MZL and CLL
cells. Actin was used as loading control.
XRCC6
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Figure 4. Quantitative real-time PCR validation for XRCC6. Relative
gene-expression quantification for XRCC6 (Ku70) and GUSB (beta-D
glucuronidase) as reference gene, in WM and other B LPD (MZL, MCL
and CLL) samples (***Po0.001 by Student’s t-test).
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Lower expression of Ku70 transcripts by quantitative RT-PCR could
be the result of at least two phenomenons: (a) genetic (point
mutation etc.) or epigenetic (promoter methylation, microRNA
etc.) mechanisms; recently described as key regulators in WM
biology;49 (b) as part of a larger transcriptional downregulation
that is, expression of BLIMP1–a transcriptional repressor —
involved in terminal differentiation of B cells to plasma cells has
been shown to shut down immunoglobulin class switching
through inhibition of activation-induced cytidine deaminase,
Ku70, Ku86, DNA-PKcs and STAT6.50
In conclusion, this is a comprehensive proteomic analysis of the
WM cells in comparison with that of two other B LPDs. This study
shows that WM harbors a unique proteome with regards to CLL
and MZL cells. A rather limited set of proteins were found to be
differentially expressed with no ‘usual suspects’ being part of this
list where the majority of proteins were rather housekeeping/
structural proteins. The conﬁrmation of the downregulation of
Ku70—part of the Ku heterodimer, a critical factor in class switch
recombination (lacking in WM)—and its mechanisms need to be
further investigated in model systems.
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